Oscotec Inc.
Oscotec Inc. has 1 licensing announcement in this dataset, dated 2026-06-01.
- Country / operating region
- South Korea
- Ticker
- 查無
- Headquarters
- South Korea
- Founded
- 1998
- Business
- Drug discovery and development
- Website
- www.oscotec.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| cevidoplenib | SYK | small molecule | phase2 | 2026-06-01 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| SKI-O-703 / cevidoplenib | PHASE2 | NCT04056195 | COMPLETED | Oscotec Inc. | 2024-07-10 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Agios Pharmaceuticals, Inc. | cevidoplenib | USD 25m | 查無 | 查無 | 查無 | Development / regulatory ≤ USD 140m |
| Counterparty | Territory | Royalties |
|---|---|---|
| Agios Pharmaceuticals, Inc. | Worldwide; Oscotec option to regain exclusive South Korea rights after Phase 3 results | High single-digit to mid-teen royalties on future net sales. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無